Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.59 |
| ▸ | HINT1 | P49773 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968582 | 1.00 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963089 | 1.00 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL31107536 | 1.00 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963095 | 1.00 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL2345479 | 1.00 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL26198 | 0.99 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL26197 | 0.99 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27658 | 0.96 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27659 | 0.96 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27352 | 0.93 | HINT1 (0.59) | ADORA2AADORA2BHINT1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | claimed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | claimed |
| EP-2361923-A2 | Oligoribonucleotides and ribonucleases for cleaving RNA | Isis Pharmaceuticals, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100151458-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7695902-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7629321-B2 | Oligoribonucleotides and oligoribonucleosides that have subsequences of 2'-pentoribofuranosyl nucleosides that activate dsRNase (double stranded RNAase) | ISIS PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090198047-A1 | 2'-Modified Oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7432250-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432249-B2 | Oligoribonucleotides and ribonucleases for cleaving RNA | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080032945-A1 | 2'-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| EP-0882061-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997046570-A1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997030067-A1 | SUGAR-MODIFIED GAPPED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0651759-A4 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. | ISIS PHARMACEUTICALS INC (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0651759-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002501-A1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | ADORA2A 132/4885ADORA2B 301/4885HINT1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.